

1 Running title: Heterologous metabolite expression in combined-culture

2

3 **Mycolic acid-containing bacteria activate heterologous secondary metabolite**
4 **expression in *Streptomyces lividans***

5

6 Hiroyasu Onaka,^{1,2†} Taro Ozaki,¹ Yukiko Mori,² Masumi Izawa,² Shohei Hayashi,¹ and Shumpei Asamizu¹

7

8 ¹Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo, Tokyo
9 113-8657, Japan

10 ²Department of Biotechnology, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398,
11 Japan

12

13 Keywords: antibiotic biosynthesis / cell-to-cell interaction / co-culture / combined-culture / heterologous
14 expression / mycolic acid / physical contact

15

1 *Streptomyces* contains 30–40 secondary metabolite biosynthetic gene clusters; however, researchers can
2 normally detect only a fraction of these secondary metabolites from a single strain under pure culture
3 conditions.¹ This suggests that the majority of these gene clusters are silent or are expressed below detectable
4 levels. The development of heterologous expression techniques has enabled us to express such genes in
5 alternative hosts, but the production level of each compound in heterologous hosts is often low and does not
6 yield a sufficient level of production. To improve the productivity of heterologously expressed secondary
7 metabolites, new methods that activate the silent or poorly expressed secondary metabolite genes are
8 required.

9 In nature, diverse groups of microorganisms form complex microbial communities. Hence, it is generally
10 believed that co-culture is a more efficient method for secondary metabolite production than a pure culture
11 because two different microorganisms in the same culture will better mimic the natural environment in which
12 microorganisms continuously interact with each other.²

13 We previously reported that bacteria containing mycolic acids in their outer membrane could induce
14 secondary metabolism in a broad range of *Streptomyces* strains.³ Mycolic acids are fatty acids that are
15 important components in forming the highly impermeable outer barrier in *Corynebacterineae*.⁴ *Streptomyces*
16 *lividans* possesses biosynthetic gene clusters for two red pigments, actinorhodin and undecylprodigiosin, in
17 its genome, but they are not produced in pure culture under normal laboratory conditions. However, *S.*
18 *lividans* starts to produce these pigments abundantly in co-culture with mycolic acid-containing bacteria such
19 as *Tsukamurella pulmonis*. This indicates that the production of these red pigments is induced by the mycolic
20 acid-containing bacteria. Interestingly, physical contact between the two strains is required for induction.
21 When cultures of *S. lividans* and *T. pulmonis* were separated by a membrane that can transfer small
22 molecules but prevents any cell-to-cell interactions, *S. lividans* did not produce the red pigments, indicating
23 that induction of gene expression is not mediated by small molecules but rather by physical contact of the
24 two types of bacteria.³

25 Co-culture with *T. pulmonis* affected secondary metabolite production in over 80.0% of soil-isolated
26 *Streptomyces* strains. Co-culture with two other mycolic acid-containing bacteria, *Rhodococcus erythropolis*
27 and *Corynebacterium glutamicum*, also changed the secondary metabolite profiles in the *Streptomyces*
28 strains by 87.5% and 90.2%, respectively.³ We defined this specific co-culture method as combined-culture,
29 which is conducted between actinomycetes and partner mycolic acid-containing bacteria for the efficient
30 production of secondary metabolites. When we used a combined-culture for antibiotic screening, novel

1 bioactive compounds such as alchivemycins from *Streptomyces endus*^{5, 6} and arcyriflavin E from
2 *Streptomyces cinnamoneus*⁷ were discovered.

3 In this study, we investigated the application range of combined-culture to heterologous metabolite
4 expression in *S. lividans*, a widely used host strain. We used the biosynthetic gene clusters for goadsporin,
5 staurosporine, and rebeccamycin, which we cloned previously,⁸⁻¹⁰ and demonstrated that production of these
6 bioactive natural products in combined-cultures was increased dramatically relative to those in pure cultures.

7 Goadsporin is a linear azole-containing peptide (LAP)¹¹ produced by *Streptomyces* sp. TP-A0584 and is a
8 morphology- and secondary metabolism-inducing substance against a broad spectrum of *Actinomycetales*.¹²
9 (Figure 1) Goadsporin is a ribosomally synthesized and post-translationally modified peptide, and its
10 biosynthetic gene cluster consists of ten genes (*godA-I*), which include one gene for the precursor peptide
11 (*godA*) and five genes for the post-translationally modification (*godD-H*).⁸ The heterologous production of
12 goadsporin in *S. lividans* has been previously achieved using the chromosome-integrating cosmid vector
13 pTOYAMAcos.¹⁰

14 We first conducted combined-culture using the goadsporin heterologous production strain (*S. lividans*
15 GSBC1)⁸ with partner mycolic acid-containing bacterial strains *Tsukamurella pulmonis* TP-B0596,
16 *Rhodococcus erythropolis* PR4 NBRC100887, and *Corynebacterium glutamicum* ATCC 13869.
17 Heterologous expression strains were first cultured in V-22 medium³ with 20 µg/mL thiostrepton at 30°C for
18 3 days on a rotary shaker at 200 rpm, and the mycolic acid-containing bacteria were cultured in V-22
19 medium at 30°C for 2 days on a rotary shaker at 200 rpm for seed culture. Three milliliters of the
20 heterologous expression strain culture and 1 mL of the mycolic acid-containing bacterium culture were
21 transferred to the same 500-mL K-1 flask containing 100 mL of A-3M medium³, and the two bacteria strains
22 were grown at 30°C on a rotary shaker at 200 rpm.

23 Goadsporin was extracted from the combined-culture, and the production amounts from days 2 to 13 were
24 measured (Figure 2a). The amounts of goadsporin in combined-culture with *T. pulmonis* and *R. erythropolis*
25 were higher than that of the pure culture during the entire measurement period, whereas the amount
26 produced in combined-culture with *C. glutamicum* was almost the same as that produced in the pure culture.
27 The amount produced in combined-culture with *T. pulmonis* reached 408 mg/L on day 12, and the amount of
28 *R. erythropolis* produced in combined-culture reached 233 mg/L on day 13. Our investigation revealed that
29 the heterologous production of goadsporin in *S. lividans* was improved by combined-culture with *T.*
30 *pulmonis* and *R. erythropolis*.

1 We next evaluated heterologous production of other compounds in combined-culture. Staurosporine and
2 rebeccamycin are produced by *Streptomyces* sp. TP-A0274⁹ and *Lechevalieria aerocolonigenes* ATCC
3 39243¹³, respectively, and are compounds that belong to the indolocarbazole family of natural products
4 (Figure 1). Rebeccamycin is an inhibitor of DNA topoisomerase I, whereas staurosporine is a potent protein
5 kinase C inhibitor. These compounds are promising antitumor drug candidates, and several derivatives are
6 currently in clinical trials.^{14,15} The staurosporine and rebeccamycin biosynthetic gene clusters consist of 15
7 and 11 genes, respectively. We constructed heterologous production mutants for both compounds as
8 described in our previous study.^{9,13} The cosmid clones pTOYAMA-Sta containing the staurosporine
9 biosynthetic gene cluster and pTOYAMA-Reb containing the rebeccamycin biosynthetic gene cluster were
10 trans-conjugated into *S. lividans* TK23, and these transformants were combined-cultured. We compared the
11 amounts of staurosporine and rebeccamycin produced in combined-culture and pure culture. The production
12 of these two indolocarbazoles in pure culture gave fairly low yields, whereas the production of each
13 antibiotic in combined-culture was significantly higher in comparison (Figure 2b and c).

14 The amount of staurosporine produced in the pure culture reached only 0.6 mg/L, and the yields did not
15 increase during the entire measurement period; however, the concentration in the combined-culture started to
16 increase after day 2 (Figure 2b). The maximum yield of staurosporine in the combined-culture with *T.*
17 *pulmonis* was reached on day 12, which produced 104 mg/L, 200-fold higher than the amount produced in
18 the pure culture. On day 12, combined-culture with *R. erythropolis* produced 39-fold more staurosporine
19 than the pure culture and that with *C. glutamicum* produced 12-fold more than the pure culture.

20 The amount of rebeccamycin produced in the pure culture remained relatively low until day 7, whereas
21 combined-culture with the three mycolic acid-containing bacteria produced more than 1.6 mg/L (Figure 2c).
22 On day 7, the combined-culture amounts produced were much higher than that of the pure culture, which
23 produced yields of 130-fold with *T. pulmonis*, 60-fold with *R. erythropolis*, and 16-fold with *C. glutamicum*.
24 After day 8, the pure culture started producing rebeccamycin but the levels paled in comparison to those of
25 the combined-cultures. The maximum production of rebeccamycin was achieved in combined-culture with *T.*
26 *pulmonis*, reaching 44.5 mg/L on day 12.

27 The heterologous expression system is a well-established technique for producing secondary metabolites.
28 However, production levels are frequently insufficient for detecting the heterologously produced compounds.
29 In this study, we evaluated the yields of two types of natural products, ribosomally synthesized and
30 post-translationally modified peptides (RiPPs)¹¹ and indolocarbazoles, in combined-culture. Our results

1 clearly showed that the yields of both product types could be increased by combined-culture. In addition,
2 production of these products in combined-culture was initiated earlier than in pure culture. Therefore,
3 combined-culture is an effective and applicable method for increasing the yield of heterologous expression
4 products in *S. lividans*.

5 Combined-culture affects a variety of secondary metabolisms not only in *S. lividans* but also in a variety
6 of *Streptomyces* species.³ It was rather surprising that products biosynthesized by heterologous gene clusters,
7 which are also regulated by different types of *Streptomyces* antibiotic regulatory proteins (SARPs), are
8 increased in combined culture. As the production of pigments was also observed in heterologous production
9 hosts (data not shown) during culturing, which is triggered by the physical contact of the two bacteria, the
10 same mechanism may be involved in incrementing heterologous metabolite production. One possibility is
11 that mycolic acid-containing bacteria stimulate the upper regulatory system, which may be globally
12 conserved in *Streptomyces* strains. In addition to activation mediated by cell-to-cell interactions, mycolic
13 acid-containing bacteria may play a role as a supplier of digested nutrients or substrates for *S. lividans* for the
14 production of heterologous antibiotics. Further transcriptional, translational and physiological analyses
15 would be required for characterization of these bacterial stimuli.

16 As combined-culture positively regulates the production of the three compounds examined in this study,
17 this method would also be applicable for secondary metabolites encoded in silent gene clusters.
18 Combined-culture, which requires only the addition of mycolic acid-containing bacteria to the pure culture,
19 can activate secondary metabolism without complicated genetic manipulation or the addition of chemical
20 inducers for secondary metabolism. Thus, this method may be advantageous for scaling up fermentation
21 volumes and is an efficient strategy for the identification and production of various secondary metabolites.

22

23 **Acknowledgements**

24 This work was supported in part by a Grant-in-Aid from the Institute for Fermentation, Osaka (H.O., T.O.,
25 and S.A.), and by JSPS KAKENHI Grants 25108707 (H.O.) and 90709057 (S.A.).

26

27 **References**

- 28 1. Ikeda H., Shin-ya K. & Omura S. Genome mining of the *Streptomyces avermitilis* genome and
29 development of genome-minimized hosts for heterologous expression of biosynthetic gene clusters.
30 *J Ind Microbiol Biotechnol.* **41**(2): 233-250 (2014)

- 1 2. Bertrand S., Bohni N., Schnee S., Schumpp O., Gindro K. & Wolfender J. L. Metabolite induction
2 via microorganism co-culture: a potential way to enhance chemical diversity for drug discovery.
3 *Biotechnol Adv.* **32**(6): 1180-1204 (2014)
- 4 3. Onaka H., Mori Y., Igarashi Y. & Furumai T. Mycolic acid-containing bacteria induce
5 natural-product biosynthesis in *Streptomyces* species. *Appl Environ Microbiol.* **77**(2): 400-406
6 (2011)
- 7 4. Marrakchi H., Laneelle M. A. & Daffe M. Mycolic acids: structures, biosynthesis, and beyond.
8 *Chem Biol.* **21**(1): 67-85 (2014)
- 9 5. Igarashi Y., *et al.* Alchivemycin A, a bioactive polycyclic polyketide with an unprecedented skeleton
10 from *Streptomyces* sp. *Org Lett.* **12**(15): 3402-3405 (2010)
- 11 6. Kim Y., In Y., Ishida T., Onaka H. & Igarashi Y. Biosynthetic origin of alchivemycin A, a new
12 polyketide from *Streptomyces* and absolute configuration of alchivemycin B. *Org Lett.* **15**(14):
13 3514-3517 (2013)
- 14 7. Hoshino S., Zhang L., Awakawa T., Wakimoto T., Onaka H. & Abe I. Arcyriaflavin E, a new
15 cytotoxic indolocarbazole alkaloid isolated by combined-culture of mycolic acid-containing bacteria
16 and *Streptomyces cinnamoneus* NBRC 13823. *J Antibiot (Tokyo).* (2014)
- 17 8. Onaka H., Nakaho M., Hayashi K., Igarashi Y. & Furumai T. Cloning and characterization of the
18 goadsporin biosynthetic gene cluster from *Streptomyces* sp. TP-A0584. *Microbiology.* **151**(Pt 12):
19 3923-3933 (2005)
- 20 9. Onaka H., Taniguchi S., Igarashi Y. & Furumai T. Cloning of the staurosporine biosynthetic gene
21 cluster from *Streptomyces* sp. TP-A0274 and its heterologous expression in *Streptomyces lividans*. *J*
22 *Antibiot (Tokyo).* **55**(12): 1063-1071 (2002)
- 23 10. Onaka H., Taniguchi S., Ikeda H., Igarashi Y. & Furumai T. pTOYAMAcos, pTYM18, and
24 pTYM19, actinomycete-*Escherichia coli* integrating vectors for heterologous gene expression. *J*
25 *Antibiot (Tokyo).* **56**(11): 950-956 (2003)
- 26 11. Arnison P. G., *et al.* Ribosomally synthesized and post-translationally modified peptide natural
27 products: overview and recommendations for a universal nomenclature. *Nat Prod Rep.* **30**(1):
28 108-160 (2013)
- 29 12. Onaka H., Tabata H., Igarashi Y., Sato Y. & Furumai T. Goadsporin, a chemical substance which
30 promotes secondary metabolism and morphogenesis in streptomycetes. I. Purification and
31 characterization. *J Antibiot (Tokyo).* **54**(12): 1036-1044 (2001)
- 32 13. Onaka H., Taniguchi S., Igarashi Y. & Furumai T. Characterization of the biosynthetic gene cluster
33 of rebeccamycin from *Lechevalieria aerocolonigenes* ATCC 39243. *Biosci Biotechnol Biochem.*
34 **67**(1): 127-138 (2003)
- 35 14. Sanchez C., Mendez C. & Salas J. A. Indolocarbazole natural products: occurrence, biosynthesis,
36 and biological activity. *Nat Prod Rep.* **23**(6): 1007-1045 (2006)

- 1 15. Nakano H. & Omura S. Chemical biology of natural indolocarbazole products: 30 years since the
2 discovery of staurosporine. *J Antibiot (Tokyo)*. **62**(1): 17-26 (2009)

3
4 **Titles and Figure Legends**

5
6 **Figure 1.** Chemical structures of natural products used in this study.

7 **Figure 2.** Production traces of (a) goadsporin, (b) staurosporine, and (c) rebeccamycin in combined-culture
8 with *T. pulmonis* (Tp), *R. erythropolis* (Re), and *C. glutamicum* (Cg) compared with those in pure culture.

9 The culture broth was extracted with an equal volume of *n*-butanol. The *n*-butanol extract was then injected
10 into an HPLC system (HP1200; Hewlett Packard, CA, USA). The sample was separated on a COSMOSIL®
11 5C₁₈ AR-II column (5 μm, 2.0 mm i.d. × 150 mm, Nacalai Tesque, Kyoto, Japan). Acetonitrile and 0.1%
12 formic acid were used as the elution solvents. The column temperature was kept at 40°C, and the flow rate
13 was 0.3 mL/min. The concentration of acetonitrile was kept at 5% for the first 2 min, linearly increased to
14 95% over the next 25 min, and kept at 95% for the next 5 min. Metabolite profiles were monitored at 254 nm
15 (for goadsporin), 292 nm (for staurosporine), and 314 nm (for rebeccamycin). The amounts of goadsporin,
16 staurosporine, and rebeccamycin were quantified using authentic standards. Staurosporine and rebeccamycin
17 were purchased from Sigma-Aldrich. Chart legends: with Tp, with Re, and with Cg represent combined
18 culture with *Tsukamurella pulmonis*, *Rhodococcus erythropolis*, and *Corynebacterium glutamicum*,
19 respectively.






Fig. 1, Onaka *et al.*




Fig. 2, Onaka *et al.*